mv1

MV1 is an antagonist of IAP. When combined with HaloTag ligand, MV1 causes protein knockdown of HaloTag-fused proteins.

MV151 is a cell-permeable, fluorescent, broad-spectrum proteasome inhibitor that specifically targets all active subunits of the proteasome and immunoproteasome in living cells and can be used to label the proteasome in vitro and in vivo.

MMV1088447 is a novel inhibitor of parasite growth. This compound shares characteristics with cells treated with nuclear hormone receptor (NHR) agonists antagonists. By reducing host lipid metabolism, MMV1088447 significantly impedes the growth of parasites.

MMV1557817 is an orally active compound that is effective against malaria. The compound exhibits good selective inhibition of aminopeptidases M1 and M17 of Plasmodium falciparum and Plasmodium vivax, and can effectively block the digestion of hemoglobin by asexual malarial parasites at the end of their life cycle.

MMV1634566 is an effective antimalarial agent that can inhibit Plasmodium falciparum and exhibits cytotoxicity.